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Abstract
Despite all the available therapies, Acute Lymphoblastic Leukemia (ALL) remains extremely difficult to eradicate. Current available
therapies, which include chemotherapy, radiation, and stem cell transplants, tend to be more successful in treating children than
adults. While adults are more likely than children to relapse after treatment, the most common cause of treatment failure in
children is also relapse. Improved outcomes for all ALL patients may depend upon new immunotherapies, specifically CAR T-cell
therapy. CAR T-cell therapy extracts a patient’s own T-cells and modifies them with a CD19 antigen. This modification allows the
new T-cells to recognize and kill cancer cells that contain the antigen on their surfaces, like leukemia cells do. Although CAR T-cell
therapy may cause toxicities such as Cytokine Release Syndrome (CRS), they are mostly short term and reversible.Trials indicate
that almost all patients who undergo CAR T-cell therapy will enter complete remission.Though a large percentage of those patients
will experience a relapse, relapse rates of CAR T-cell therapy are lower than other treatments. By reviewing the available research
literature regarding CAR T-cell therapy, this paper examines the effectiveness of this therapy in different patient populations and
demonstrates that CAR T-cell therapy significantly improves event-free survival rates in ALL patients.
Acronyms Used:
ALL - Acute Lymphoblastic Leukemia
ACT - Adoptive Cell Transfer
CAR - Chimeric Antigen Receptors
CRS - Cytokine Release Syndrome
CSF - Cerebrospinal Fluid
Ph - Philadelphia chromosome
TKI - Tyrosine Kinase Inhibitors
CNS – Central Nervous System
WBC – White Blood Count

Introduction
The leading cause of disease related death in U.S. pediatric patients is cancer, most commonly Acute Lymphoblastic Leukemia
(ALL) (Tumaini, et. al., 2013). For many years, cancer treatments
were limited to radiation therapy, chemotherapy, or surgery. More
recently, newer types of treatments called immunotherapies, have
become available. Cancer immunotherapies are therapies that
enlist and strengthen the power of a patient’s immune system to
fight and attack the cancer. Of the immunotherapies discovered,
adoptive cell transfer (ACT), in which a patient’s own immune
cells are collected and used to treat their cancer, has achieved
the most successful outcomes. The most effective ACT therapy
is CAR T-cell therapy (Brentjens, et. al., 2013). In 2017, CAR T-cell
therapy was approved by the FDA as a treatment for ALL and for
adults with advanced forms of lymphoma. However, while it may
seem that CAR T-cell therapy is poised to revolutionize cancer
therapy, some of the optimism surrounding it is tempered by concerns about its safety and potentially severe toxicities (Lim, June,
2017), calling into question if CAR T-cell therapy is an improved
treatment for ALL and relapsed ALL.

Methods
The research used in this paper was located and compiled
from papers obtained through Touro College’s access to online publications. Google Scholar and Blood Journal were used
for additional references. The articles were critically selected,
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compared, and analyzed to evaluate if CAR T-cell therapy is an
effective treatment for ALL.

CAR T-cell Therapy
CAR T-cell therapy is relatively straight forward. T-cells, which
play a critical role in orchestrating an immune response, are responsible for killing cells that are infected by pathogens. In order
to retrieve these T-cells, blood is drawn from a patient and the
T-cells are separated from the rest of the blood.The T-cells then
undergo genetic modification via the insertion of genes that
encode for tumor specific chimeric antigen receptors (CARs).
These receptors allow the T-cells to recognize and subsequently
attach to a specific antigen. The antigen CD19 was chosen because it is universally expressed on all ALL tumor cells and not
on pluripotent hematopoietic stem cells (Tumaini, et. al., 2013).
Once the T-cells have been successfully engineered to express
the CD19 antigen, they are expanded in a lab to form hundreds
of millions of cells. This process has been refined and advanced
over the years and can now quickly create large quantities of
T-cells that have genetically engineered receptors on their surface to treat both pediatric and adult ALL patients. The CAR
T-cells are then infused back into the patient’s body where they
continue to multiply, recognize, and kill the cancer cells containing the antigen on their surfaces (Tumaini, et. al., 2013). This
step is considered to be an in vivo expansion, which requires
the new host to support these engineered T-cells.Therefore, the
administration of the T-cells is preceded by a lymphodepleting
regimen, as lymphopenia (the condition of having an abnormally
low level of lymphocytes in the blood) generates changes that
support T-cell expansion and survival (Klebanoff, et. al., 2005). As
a result, most adoptive cell therapy protocols incorporate some
version of lymphotoxic therapies prior to cell transfer.
Like most cancer treatments, CAR T-cell therapy has serious
side effects. The most common side effect that patients usually
experience is cytokine release syndrome (CRS). Notably, CRS
has been seen in patients treated with other immunotherapies
and is therefore not limited to CAR T-cell therapy (Lee, et.
al., 2014; Teachey et al., 2013). CRS is caused by the cytokines
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released from the T-cells as CAR T-cells rapidly expand within
the patient’s body. It can also be caused by other immune cells,
such as macrophages that might produce cytokines in response
to the cytokines produced by the infused CAR T cells. CRS
patients have high levels of IL-6 (the cytokine secreted by the
T-cells) and is characterized by systemic symptoms that usually
begin with a fever (Giavridis, et. al., 2018).The onset of the fever
can range from a few hours after the treatment to more than
a week after CAR T-cell infusion (Brudno, Kochenderfer, 2016).
The fever is followed by nausea, chills, headaches, muscle pain,
and difficulty breathing (Maude et al., 2014).
CRS can lead to many different related toxicities that attack
organ systems. Cardiovascular toxicities most commonly cause
tachycardia, although more severe cases of CRS have prompted
hypotension, arrhythmia (irregular heartbeat), and decreased
cardiac ejection fraction. CRS can lead to pulmonary edema
and hypoxia, the deficiency in the amount of oxygen reaching
the tissues that may require mechanical ventilation. It can also
lead to reduced renal perfusion, the volume of blood delivered
to the kidneys per unit time, which can cause a kidney injury.
However, CAR T-cell related renal injuries are mostly reversible.
The same goes for other laboratory abnormalities that CRS
causes, such as elevated levels of bilirubin and/or serum transaminases. Patients also commonly become neutropenic and
lymphogenic when undergoing and following CAR T-cell therapy
because they are severely immunocompromised and are not
protected against opportunistic infections, such as salmonella,
bacteremia, and urinary tract infections. Viral infections such as
influenza, respiratory syncytial virus, and herpes zoster virus,
have also been known to affect patients following CAR T-cell
infusion (Brudno, Kochenderfer, 2016). Unfortunately, in such a
setting, fevers, tachycardia, hypotension, and other regular symptoms associated with CRS can be difficult to differentiate from
sepsis, which is a life-threatening infection. In an early trial, a
patient with chronic lymphocytic leukemia who received chemotherapy prior to his CAR T-cell treatment died with fever,
hypotension, and renal failure four days after the administration
of the CAR T-cells. It was discovered later that there were elevated serum levels of inflammatory cytokines before CAR T-cell
infusion, suggesting that the patient had a prior infection that
caused his death (Brentijens, Curran, 2012).
CAR T-cell therapy also has neurological toxicities associated
with the treatment. The toxicities can be diverse, as they do
not always localize to one specific area of the nervous system.
The occurrence of neurologic toxicity is quite variable, with
published reports stating that there is a 0% to 50% chance of
neurological toxicities developing (Brudno, Kochenderfer, 2016).
Neurologic events are not always associated with CRS toxicities, which suggests that in some cases, they might have a different mechanism than many of the other usual toxicities caused
by CRS, such as fever and hypotension (Maude, et. al., 2014).

Ironically, CRS is considered to be an “on-target” effect of
CAR T-cell therapy, as the presence of the cytokines show that
the T-cells are working in the body. Various grading systems for
the “CRS-related adverse events” caused by immunotherapies
have been proposed. They depend on many things, such as the
temperature of the fever, the number of severe signs of toxicities, and cytokine levels in the patient. A category of severe CRS
is defined as CRS requiring pharmacologic and medical intervention. In such cases, tocilizumab, an IL-6 receptor antagonist
that is used to treat rheumatologic disorders, is used as a first
line agent. While not approved for this use by the FDA, it has
effectively treated CRS-related toxicities in clinical trials with no
life threatening or toxic effects (Maude, et. al., 2014), and is now
a widely used off-label for the patients who have received CAR
T-cell infusions. (Brudno, Kochenderfer, 2016).
Systemic corticosteroids have also been used for CRS-related
toxicities. However, there is some evidence that corticosteroids
can possibly inhibit CAR T-cell persistence and anti-malignancy
efficacy. For this reason, corticosteroid therapy is only used as a
last resort if the tocilizumab does not succeed in ameliorating
the CRS. However, because neurologic toxicities may not come
along with CRS, these toxicities may differ from that of CRS
alone. It is unclear if tocilizumab has any beneficial effect on neurologic toxicities, as severe neurologic toxicities are commonly
treated with systemic corticosteroids right away, rather than
initially beginning with tocilizumab.
Toxicities caused by CAR T-cells are diverse. Management
of these toxicities requires continuous and vigilant monitoring,
aggressive supportive treatments, and, in some cases, intensive
care. Another harmful side effect of CAR T-cell therapy is that
the engineered CAR T-cells with the CD-19 receptor could damage other tissues that express the antigen recognized by it. This
mechanism of toxicity can be mostly eliminated by searching for
any expression of the targeted antigen on normal tissues in the
body prior to the development of the CAR (Lamers, et. al., 2013).

Other Therapies
There are several other therapies used to treat ALL. The goal
of these treatments is to remove all traces of the ALL from the
patient. The most commonly used treatment for ALL is chemotherapy. The chemo treatment is divided into three phases. The
first stage is known as the induction phase and usually takes
about a month. The next phase, consolidation, also referred to
as intensification, is, as its name suggests, extremely intense as
well, and typically lasts for a few months. The last phase, maintenance, or post-consolidation, is less intensive, and lasts for about
two years (Pui, et. al., 2008).
The goal of induction, is to remove more than 99% of the
initial leukemia cells from the patient and to restore normal
haemopoiesis, the production of blood cells and platelets in the
bone marrow. Afterwards, if both the blood and bone marrow
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show no evidence of persistent leukemia and blood counts have
returned to normal, then the patient achieves remission. Studies
show that 96 to 99% of children with ALL enter remission after
the induction treatment. Adults have a lower remission rate with
only 78-93% of adults entering clinical remission (Pui, et. al., 2008).
Nevertheless, a remission is not necessarily a cure, and since the
first month is such intense treatment, many complications and
serious infections can arise. As a result, this phase of treatment
requires lengthy hospital stays and frequent visits to the doctor,
as these complications can be life-threatening. Recent advances in
supportive care have helped lower these complication rates, making them considerably less common than they have previously
been. Examples of supportive care are better nursing care, proper nutrition, prescribed antibiotics, and red blood cell or platelet
transfusions as needed (Locatelli, et. al., 2012).
There are three major types of drugs that children with standard-risk ALL receive during the first month of treatment.These
are chemotherapy drugs L-asparaginase and vincristine, as well
as a steroid drug, usually dexamethasone (Goekbuget, et al.,
2005). For children in high-risk groups, a fourth drug from the
anthracycline class, typically daunorubicin, is added. ALL patients
also require chemotherapy via the cerebrospinal fluid (CSF), as
there may be leukemia cells that spread to the brain and spinal
cord. This treatment is known as intrathecal chemotherapy and
given through a lumbar puncture/spinal tap. Patients with high
risk leukemia or leukemia in their CSF receive this treatment
more frequently than other ALL patients do. In the past, along
with intrathecal therapy, patients were also given prophylactic
cranial irradiation. Recent studies have found that children who
are given more intensive chemotherapy may not need radiation therapy at all. Doctors try to avoid giving radiation to the
brain, especially in younger children, because even low doses
may result in problems with cognition, growth, and development
(Locatelli, et al., 2012).
The next phase, consolidation, is the phase of chemotherapy
that further reduces the number of leukemia cells still in the body.
Several chemo drugs are used together to prevent the remaining
leukemia cells from developing a resistance. Intrathecal therapy is
continued at this time, and patients with high-risk leukemia usually receive more intense chemotherapy. During this phase, patients
with Philadelphia chromosome-positive ALL may benefit from the
addition of other types of cancer therapies, such as targeted cancer drugs or stem cell transplants (Pui, et. al., 2008).
If the leukemia remains in remission after induction and
consolidation, the third phase, maintenance therapy, can begin.
Most treatments use medication given either as pills or intravenously, and a steroid, usually prednisone or dexamethasone.
Depending on the type of ALL and the risk of recurrence, other
drugs may be added as needed. In the beginning of the maintenance phase, most treatment plans include one or two repeat
intensified treatments like the initial induction. These four-week

34

intensifications are called re-induction or delayed intensification.
Some children at higher risk may receive more intense maintenance chemotherapy and intrathecal therapy. The total length
for the three phases of chemotherapy for most ALL treatment
plans is two to three years. However, patients with a higher risk
of relapse are given several extra months of treatment as an
added precaution (Pui, et. al., 2008).
Throughout the entire chemotherapy process, the combination of anti-cancer drugs used often causes serious side effects.
This is mainly because the chemotherapy drugs affect healthy
body cells as well cancer cells. Many organs, such as the kidneys, liver, testicles, ovaries, and lungs, can be damaged by these
drugs. In an effort to reduce the number of side effects, the
chemotherapy is given in cycles, and each round of treatment is
followed by a rest period, so the body has time to recover. Some
of the main side effects of chemotherapy are loss of hair and
appetite, vomiting and nausea, constipation, and mouth sores.
Chemo drugs also affect the normal cells in bone marrow, which
can lower blood cell counts. This leads to an increased risk of
infections, due to low white blood cell counts, easy bleeding
and bruising from low platelet counts, and constant fatigue and
shortness of breath, as patients do not have enough red blood
cells (hemoglobin) to carry the oxygen needed in their bodies
(Pui, et. al., 2008).
As with most treatments, steps can be taken to reduce the
toll these side effects can have on the patients. Drugs, such as
Ondansetron (Zofran) can be given to decrease nausea and
vomiting. Transfusions or drugs can be administered to raise
a platelet or red blood cell count, and antibiotics are given
at the earliest sign of a developing infection. Even tumor lysis
syndrome can be prevented. This potentially life-threatening
side effect of chemo is usually seen in the induction phase of
treatment. As the leukemia cells are killed by the chemo drugs,
they break open, releasing their contents into the bloodstream.
These components can overwhelm the kidneys because they
are unable to filter out and remove all these substances from
the blood at once, and the excess amounts of certain minerals
can affect the heart and nervous system. Administering certain
drugs and extra fluids during treatment can help the body eliminate these substances (Goldman, et. al., 2001). Patients need to
be carefully monitored while being treated with cancer drugs to
reduce the risk of these side effects as much as possible.
High-energy radiation used to kill cancer cells is another
therapy used to treat ALL. Most often, external beam radiation
therapy is used, in which a machine delivers a beam of radiation
to a specific part of the body at a certain angle. Although radiation is not used as the main treatment for ALL, it is used in certain situations, such as preventing or treating leukemia that has
spread to the brain, (though lately, radiation has been omitted
from treatment plans) spinal fluid, and testicles. Before a bone
marrow or peripheral blood stem cell transplant takes place,
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the whole body often needs radiation. Rarely, radiation can help
shrink a tumor if it is causing breathing problems by pressing on
the trachea, although chemotherapy is often used instead, as it
normally achieves the same effect more rapidly (Cherlow, et. al.,
1993). The side effects of radiation therapy depend on the location at which the radiation beam was targeted. The treated area
can appear sunburned and undergo hair loss. Radiation to the
abdomen can sometimes cause nausea, vomiting, or diarrhea.
Effects of radiation that targets large parts of the body may include fatigue, shortness of breath, and an increased risk of infection due to lower blood cell counts (Pearce, et. al., 2012).
One of the most serious, but not very common side effects of
ALL chemotherapy and radiation therapy is an increased risk of
getting another neoplasm, a new and abnormal growth of tissue
in some part of the body that can become cancerous later on.
Although effective treatments for ALL now result in five-year
survival rates above 70%, the treatments used are ironically
carcinogenic. Studies show that there is a substantial chance
of secondary neoplasms among patients treated for ALL with
chemotherapy and radiation. Children five years old and under,
as well as patients who received radiation as a form of therapy,
are at a higher risk for second tumors arising in their central
nervous system, as well as patients who received radiation as a
form of therapy. (Neglia, et. al., 1991).
Allogenic hematopoietic stem-cell transplantation, the transplantation of multipotent hematopoietic stem cells, is the most
intensive form of treatment for ALL. This stem cell transplantation seems to benefit several types of high risk ALL patients,
such as patients with poor initial responses to treatments,
patients who have relapsed, and those with Philadelphia chromosome-positive disease (Pui, et. al., 2008). The Philadelphia
chromosome (Ph) is the most frequent cytogenetic abnormality in adult ALL. Most patients with Ph+ ALL cannot be treated
with chemotherapy alone, as chemotherapy can only induce a
complete remission for a few months until most patients experience a relapse. The five-year survival rates for those who have
Ph+ ALL and were treated with chemotherapy alone are less
than 10%. However, those who underwent allogenic stem cell
transplantation during early remission have a 35-65% chance of
long-term survival (Lee, et. al., 2005). Bone marrow transplants
(BMT) are sometimes needed as well for patients with underlying malignancies or genetic disorders (Slavin, wt. al., 1998).
Targeted cancer drugs are also being used as a treatment for
ALL. Cancer cells are cells that undergo changes to their genes.
These changes cause the cancer cells to grow faster and work
differently from others. Targeted cancer drugs use these differences in cell genes to differentiate them from other normal cells
and target the specific gene changes. The main targeted cancer
drugs used for ALL are tyrosine kinase inhibitors (TKIs). They
block tyrosine kinases, chemicals that cells use to signal to each
other.The main side effects of targeted cancer drugs, specifically

TKIs, are fatigue, a sore mouth, rashes or reddening of the skin,
and loss of appetite (Pui, et. al., 2008).

Success Rates
Chemotherapy affects children and adults with ALL differently.
Children that undergo chemotherapy treatment have a much
greater chance of survival than adults, yet only 80 – 85% of
children can be cured. A large chemotherapy trial comprised
of children up to eighteen years old was conducted on 1,114
patients. Of those patients, only 998 became protocol patients,
and were divided into three groups; a standard risk group, those
without central nervous system (CNS) disease, a risk group,
those with CNS disease, and an experimental group.They all received induction therapy and some variation of continued chemotherapy, including cranial irradiation as needed. Additionally,
an intensive reinduction therapy was added for patients in the
standard risk group who had increased risk of failure during the
trial. The event-free survival for the 110 patients who did not
receive reinduction therapy was almost 30% lower than those
with reinduction therapy. In this trial, a complete remission was
measured by several parameters: the absence of leukemic cells
in the blood and CSF, fewer than 5% lymphoblasts in marrow,
and no evidence of localized disease. Relapse was defined as
reappearance of lymphoblasts or localized leukemia infiltrates
at any site (Reiter, et. al., 1994).
Figure 1 presents results of this trial. Of the 998 patients, 985
(98.7%) entered complete remission. Thirteen patients did not
enter remission; seven had resistant leukemia, one died of renal
failure, and five died an early toxic death. At the 5.0-year (range
3.4 - 6.9 years) median follow up, 233 patients experienced a
relapse (23.3%). Thirteen more patients died while in complete,
continuous remission and three patients developed a second
malignancy. There were 734 patients (73.5%) still in their first
continuous complete remission.
The six-year, event-free survival estimate was for 888 patients. The 110 patients who did not receive reinduction were
excluded from this estimate. Of all three branches together, the
estimate was 74% ± 2%. Detailed analysis showed that male patients had higher white blood counts (WBC), were six years
old or greater, or had T-ALL, had a better outcome than others.
For example, 69% ± 5% of T-ALL patients with WBC ≥ 20,000/
μL had event-free survival at six years. This is a comparatively
larger number than 58% ± 3% for the complementary group of
patients with an immunophenotype other than T-cell ALL. These
other immunophenotypes had no predictive strength for treatment outcome (Reiter, et. al., 1994).
There was a trial for 525 patients under 19 with a first-time
relapse of T-cell or B-cell ALL. The patients were treated with
intensified, short course multi drug chemotherapy. A major aim
of this study was to improve outcomes through a third intensive chemotherapy course (R3) containing HD cytarabine and
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cell transplantation is available.
Prevention of recurrence would
998 Patients
be the best strategy for long-term
survival from this disease (Fielding,
et. al., 2007).
998 Patients:Complete
13 Patients:
remission
7 Resistant Leukemia
The most common cause of
(98.7%)
6 Died
ALL treatment failure is relapse,
as approximately 15 – 20% of
*16 Patients died
children experience relapse. With
*734
Patients(73.5%)
were
*233 Patients Relapsed
13 in complete continuous
still in their first continuous
intensive chemotherapy and transremission
(23.3%)
remission
3 from second malignancy
plantations, 30-50% of all children
with relapsed ALL can be cured.
Figure 1: Breakdown of patients in the trial
*5.0 year (range 3.4 - 6.9) median follow up
However, because relapsed ALL is
etoposide. Results showed that 440 patients (84%) achieved a
difficult to treat, most relapsed children still die, despite the
second complete remission, 25 patients (5%) died during inaggressive therapies (Locatelli, et. al., 2012). CAR T-cell therapy
duction, and 60 patients (11%) did not respond to treatment.
may be able to overcome the limitations of conventional theraThirty-one patients (6%) died in the second complete remispies and induce remission in patients with relapsed and refracsion as a result of treatment-related adverse effects. Of those
tory ALL (Maude, et. al., 2014). In one trial, thirty patients were
patients who achieved second complete remission, 246 patients
selected. Twenty-five patients were aged from five to twen(56%) suffered subsequent relapse, and six patients (1%) expety-two, and the other five patients between twenty-six and sixty.
rienced a secondary malignant neoplasm. At a median follow-up
Of these patients, twenty-six had B-cell ALL in a first to fourth
of twelve years, 153 (29%) of 525 patients remained in comrelapse, three had primary refractory B-cell ALL, and one paplete continuous remission. The study concluded that neither
tient had relapsed T-cell ALL. Eighteen patients had experienced
R3 nor adaptation of chemotherapy intensity was capable of
their relapsed ALL after allogenic stem-cell transplantation. All
improving event-free survival or of overcoming prognostic facthe patients in this study experienced CRS. Eight patients develtors. Therefore, induction regimens need to be improved for
oped severe CRS, and all required respiratory support and vahigh risk patients, and allogeneic stem cell transplant should be
sopressor support for hypotension. However, all neurotoxicity
recommended in patients achieving second complete remission
was reversible and there was no lasting damage form the CRS
(Tallen, et. al., 2010).
(Maude, et. al., 2014).
Adult recovery rates are not as high as children’s. ALL acOne month after the infusion, twenty-seven patients (90%)
counts for about 15 – 20% of all adult leukemias. Although some
obtained complete remission. Of these patients, nineteen
of these patients enter complete remission, most of them reremained in remission. Fifteen patients received no further
lapse and die. With chemotherapy alone, those younger than
therapy, and five withdrew to receive other treatments. At six
sixty have a 30 - 40% chance of recovery (Mohty, et. al., 2010).
months, the event-free survival rate was 67%, and the overall
Anyone older than sixty has less than 10% chance. In many
survival rate was 78%. This is a much better rate than the <25%
cases, chemotherapy is not enough and adult patients need
complete remission rates of the recently approved drugs (nelarother therapies, such as transplants. However, the patients still
abine, liposomal-encapsulated vincristine, and clofarabine) for
need to undergo chemotherapy maintenance after the inducALL. This study showed an encouraging sustained remission of
tion therapy and transplant. (Goldstone, et. al., 2008).
up to two years (Maude, et. al., 2014).
A study was performed on 609 adults with relapsed ALL, all of
In another trial, 53 pretreated adults received CAR T-cell
whom were previously treated in the Medical Research Council
therapy. A total of thirty-six patients (68%) received CAR T-cell
study, in which the overall survival of newly diagnosed patients
therapy as a third or later salvage treatment, twelve had primary
was 38% at 5 years. By contrast, in this chemotherapy study,
refractory disease, nineteen had undergone allogeneic hemathe overall survival at 5 years after relapse was 7%. Factors
topoietic stem-cell transplantation previously, and thirteen had
predicting a good outcome after salvage therapy were young
received the drug blinatumomab previously. A total of sixteen
age (overall survival of 12% in patients younger than 20 years
patients had Philadelphia chromosome positive ALL, and ten of
vs overall survival of 3% in patients older than 50 years) and
the sixteen patients had disease that was refractory to the drug
short duration of first remission. Treatment received in the first
ponatinib. After infusion, 26% of the patients had severe CRS.
complete remission did not influence the outcome after relapse.
Complete remission was defined as less than 5% bone marrow
This study concluded that adults who have an ALL relapse canblasts, the absence of circulating blasts, and no extramedullary
not be rescued using currently available therapies, even if stem
sites of disease regardless of cell-count recovery. Relapsed
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disease was defined as the reappearance of blasts in blood or
bone marrow or in an extramedullary site after a complete
remission. One patient died from multiorgan failure and severe
CRS on day five, and complete remission was observed in 83%
of the patients. At a median follow-up of twenty-nine months
(range one to sixty-five), the median event-free survival was 6.1
months, and the overall survival was 12.9 months. Patients with
a low disease burden (<5% bone marrow blasts) before treatment had distinctly enhanced remission duration and survival,
with a median event-free survival of 10.6 months and a median
overall survival of 20.1 months. Patients with a higher burden
of disease (≥5% bone marrow blasts or extramedullary disease)
had a greater incidence of the cytokine release syndrome and
neurotoxic events and shorter long-term survival than did patients with a low disease burden. This is a better outcome than
the three to nine months of median overall survival seen from
chemotherapy (Park, et. al., 2018).
Of the 44 patients who had a complete remission after the
infusion of CAR T-cells, 26 did not undergo further therapy,
including nine who were alive and seventeen who had a relapse or died. One patient received alternative treatment for
minimal residual disease–positive disease, and seventeen patients progressed to transplantation. The median time from the
CAR T-cell infusion to transplantation was 74 days (range, 44
to 312). Of the seventeen patients who underwent allogeneic
transplantation after the CAR T-cell infusion, five patients were
alive and had a complete remission, six had a relapse, and six
died from transplant-related toxic effects. This study showed
that CAR T-cell therapy had favorable long-term remission rates
in a population of patients with low disease burden, who had
significantly longer event-free survival and overall survival with
markedly lower incidences of toxic effects than did those with
a high disease burden (Park, et. al., 2018).
In another trial, 20 patients (aged 1-30 years, including eight
patients who underwent allogenic stem-cell transplantation)
with relapsed or refractory ALL were infused with CAR T-cells.
CRS was recorded in 16 patients, and all toxicities associated
with the therapy were reversable. Complete remission was observed in 70% of the patients. Many of the patients in the trial
underwent further stem cell transplantation therapy, which led
to the conclusion that CAR T-cell therapy is an effective bridge
to stem cell transplantation for patients with chemo refractory
B-ALL. Because most patients who entered remission eventually
underwent stem cell transplantation, this study was not able to
assess the durability of response to the CAR T-cells, yet it was
associated with a favorable long-term survival. Additionally, this
study showed that CAR T-cells mediate a complete remission
in refractory ALL that is substantially higher than the 8-20%
reported with clofarabine, a drug that was approved in 2004 for
refractory pediatric ALL (Lee, et. al., 2014).

Conclusion
CAR T-cell therapy is currently being used as a treatment for
patients who have already been treated with other therapies
and relapsed. This makes the effectiveness of the therapy difficult to gauge, as CAR T-cell therapy trial outcomes cannot be
compared to first time treatment data of other therapies such
as chemotherapy. Nevertheless, the trials have shown that the
toxicities from CAR T-cell therapy are manageable and are no
longer a big concern. The trials also show that although it does
not have perfect results, CAR T-cell therapy is far more successful in treating relapsed ALL than other therapies have been,
as the complete remission rates and longer survival rates are
higher for relapsed ALL than any other treatment. Some studies
indicated that many patients may have needed additional stem
cell transplants and other therapies after undergoing CAR T-cell
therapy, so it cannot always be used as a lone therapy. However,
some patients did achieve event-free remission from only CAR
T-cell therapy. There were no attempts in proving that CAR
T-cell therapy should not be done, making this therapy a great
treatment option for ALL, especially relapsed ALL.
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